Summaries for patients. Cost-effectiveness of alendronate in postmenopausal women with low bone mass without osteoporosis or previous fracture.
D000368:Aged; D019386:Alendronate / Q000191:economics* / Q000627:therapeutic use*; D015519:Bone Density; D001851:Bone Diseases, Metabolic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans; D008137:Longitudinal Studies; D008390:Markov Chains; D008875:Middle Aged; D017698:Postmenopause; D012307:Risk Factors
D019386:Alendronate